Life Sciences

  • February 13, 2026

    Iowa AG Urges 8th Circ. To Unblock Parts Of State PBM Law

    The state of Iowa urged the Eighth Circuit on Friday to lift a preliminary block on parts of a law limiting pharmacy benefit managers' power to set drug prices in the Hawkeye State, arguing a lower court judge erred in holding that parts of the policy were federally preempted.

  • February 13, 2026

    FDA Removes Boxed Warnings From HRT Products

    Six menopause hormone therapies will no longer have warnings on their label about heart disease, breast cancer and dementia, after the U.S. Food and Drug Administration said it removed them so that women can make decisions "free from exaggeration or fear."

  • February 13, 2026

    How Attorneys Are Handling A Patent Review 'Sea Change'

    Major changes to the America Invents Act patent review system over the past year have put limits on challenges, requiring patent challengers and owners to rethink their strategies. Here's how attorneys on both sides are calibrating their arguments to have the best chance of success in the new landscape.

  • February 13, 2026

    J&J Hit With $250K Verdict In 2nd Philly Talc Trial

    A Philadelphia jury hit Johnson & Johnson with a $250,000 verdict on Friday, finding the company liable in the case of a woman whose family claimed that using the company's once-famous talcum powder contributed to her fatal ovarian cancer.

  • February 13, 2026

    CareDx Seeks High Court Review Of $45M False Ad Case

    Transplant diagnostics company CareDx has asked the U.S. Supreme Court to review a Third Circuit decision that erased a nearly $45 million jury award against rival Natera in a false advertising case, arguing the appeals court is the only one that forbids juries from inferring consumer deception when determining damages.

  • February 13, 2026

    Prenatal Testing Co. Missed Fatal Condition, Couple Say

    A Massachusetts couple say Natera Inc. misreported the results of tests for a genetic marker linked to a fatal kidney condition, leading to the conception of a child who died an hour after birth.

  • February 12, 2026

    FTC's PBM Case Paused For More Deal Talks

    Federal Trade Commission staffers are discussing potential settlements with OptumRx and Caremark that could end the agency's case accusing the pharmacy benefit managers of inflating insulin prices, following a recent deal with Express Scripts.

  • February 12, 2026

    Ex-Pharma Exec Fights AGs' Quick Win Bid In Antitrust Case

    A former pharmaceutical marketing executive urged a Connecticut federal court to reject summary judgment sought against him by state attorneys general pursuing wider price-fixing litigation against most of the generic drug industry, arguing key cooperating witnesses' questionable credibility makes a trial necessary.

  • February 12, 2026

    Astellas Gets $120M From Zydus In Bladder Drug Deal

    Generic-drug maker Zydus Pharmaceuticals has inked a $120 million deal to end a lawsuit accusing it of infringing Astellas Pharma Inc. patents covering bladder drug Myrbetriq, just two days after Lupin Pharmaceuticals made a similar deal.

  • February 12, 2026

    Goodwin Expands Healthcare Team With Ex-Reed Smith Atty

    A healthcare attorney specializing in guiding clients through regulatory and transactional matters has moved her practice to Goodwin Procter LLP's Philadelphia office after more than 11 years with Reed Smith LLP.

  • February 12, 2026

    Regeneron, Samsung Bioepis Settle Eye Med Patent Claims

    Regeneron Pharmaceuticals Inc. and Samsung Bioepis Co. Ltd. have told a West Virginia federal court they reached an agreement to end patent infringement claims brought by Regeneron over a biosimilar of its eye medication Eylea.

  • February 12, 2026

    McKesson Freed From Opioid Death Suit By Ga. Panel

    The Georgia Court of Appeals said Thursday that drug distributor McKesson should have been freed from a suit attempting to hold it liable for a man's opioid overdose death, saying that a trial court applied the wrong statute of limitations to what was, at its core, a personal injury claim.

  • February 11, 2026

    AbbVie Sues Medicaid, HHS Over Botox Fair Price Controls

    AbbVie Inc. on Wednesday asked a D.C. federal court to block the Centers for Medicare and Medicaid Services from controlling the price of Botox under the Inflation Reduction Act, arguing the cosmetic drug and migraine treatment should be excluded from the controls because it's a "plasma-derived" product.

  • February 11, 2026

    Pfizer, SEC Reach $29M Deal In Insider Trading Fund Dispute

    Pfizer and the U.S. Securities and Exchange Commission have jointly asked a New York federal judge to allow $29 million out of the roughly $75.2 million distribution leftover from a $602 million insider trading deal to be paid out to a Pfizer subsidiary.

  • February 11, 2026

    Luxottica Franchisee Gets Another Shot At Antitrust Claims

    An Ohio federal judge partially reversed course Wednesday after previously permanently tossing a Luxottica franchisee's antitrust claims, concluding that an attempt to amend them wouldn't be futile because it might be possible to show that allegedly suppressed insurance reimbursement rates were an ongoing violation that resets the statute of limitations.

  • February 11, 2026

    Biogen Beats Pharmacies' MS Drug Monopoly Suit, For Now

    An Illinois federal judge on Wednesday tossed out Walgreens and Kroger's lawsuit accusing Biogen Inc. of illegally stifling competition for its multiple sclerosis drug Tecfidera, but said the standing issues primarily dooming their complaint can likely be cured if they amend their pleading.

  • February 11, 2026

    NY Judge Rejects Bid To Stop SD Action Against Abortion Ads

    A New York federal judge said Wednesday that she can't block South Dakota officials from pursuing state legal action against an abortion rights group that launched an advertising campaign in South Dakota, saying she doesn't have jurisdiction to halt the proceedings.

  • February 11, 2026

    Supreme Court Sets April Argument For 'Skinny Label' Case

    The U.S. Supreme Court has set an April 29 date for oral arguments in Hikma Pharmaceutical Inc.'s appeal of a decision that revived a patent case over its "skinny label" on a generic heart drug.

  • February 11, 2026

    7th Circ. Mulls Expiration Date Of Teva, Eli Lilly Patent Deal

    Seventh Circuit judges Wednesday pressed counsel for Teva Pharmaceuticals USA Inc. to address how long a settlement under which Eli Lilly & Co. agreed not to block the approval and marketing of Teva's generic version of its osteoporosis drug Forteo could reasonably remain in effect, given Teva's drug wasn't ready for market until years after the underlying patent dispute.

  • February 11, 2026

    Shkreli Can't Add Wu-Tang Members To Fight With Crypto Co.

    "Pharma Bro" Martin Shkreli can't drag two members of the Wu-Tang Clan hip-hop group into a suit brought by a crypto firm that claims Shkreli improperly retained copies of an album that it bought the rights to, a New York federal judge ruled on Wednesday.

  • February 11, 2026

    Beasley Allen Wants Talc DQ Paused Pending High Court Appeal

    Hundreds of women who claim their ovarian cancer was caused by Johnson & Johnson's talcum powder risk appearing in an upcoming trial without their preferred counsel from the Beasley Allen Law Firm, unless a New Jersey state court stays an order disqualifying the firm, it said.

  • February 11, 2026

    Trans Health And Pediatric Groups Challenge FTC Subpoenas

    A major transgender medical group and a pediatric healthcare organization are seeking to end what they call "unlawful" consumer protection investigations from the Federal Trade Commission that want information pertaining to the medical groups' claims made in their marketing and advertising for gender-affirming care for minors. 

  • February 10, 2026

    Judge Limits Insurers' Exposure in Opioid Coverage Fight

    Insurers garnered several wins Tuesday in a dispute over coverage for thousands of opioid suits against bankrupt pharmaceutical company Endo International, with a Pennsylvania federal court ruling favorably for the carriers on the interpretation of claims-made provisions and the meaning of "damages for bodily injury."

  • February 10, 2026

    GSK, Teva Settle 'Skinny Label' Heart Medication Suit

    GlaxoSmithKline and Teva told a Delaware federal judge that they've settled GSK's decade-long "skinny label" patent fight over heart failure medication and asked the court to end the case.

  • February 10, 2026

    Jury Asked To 'Send A Message' To J&J As Talc Trial Wraps

    Counsel for a woman who died of ovarian cancer asked a Philadelphia jury to "send a message" with its verdict at the closing of the court's second talc mass tort trial against Johnson & Johnson, suggesting they should consider the company's multibillion-dollar net worth when coming up with a punitive damages award.

Expert Analysis

  • Surveying The Healthcare Policy Landscape Post-Shutdown

    Author Photo

    With last week's agreement to reopen the federal government, at least through the end of January, key healthcare legislation that has been in limbo since a December 2024 spending bill fell apart may recapture the attention of Congress, say attorneys at Faegre Drinker.

  • FDA Biosimilar Guidance Should Ease Biologics Development

    Author Photo

    New draft guidance from the U.S. Food and Drug Administration, indicating that the agency may no longer routinely require comparative efficacy studies when other evidence provides sufficient assurance of biosimilarity, underscores the FDA's trust in analytical technology as a driver of biologics access, say attorneys at Hogan Lovells.

  • Litigation Funding Could Create Ethics Issues For Attorneys

    Author Photo

    A litigation investor’s recent complaint claiming a New York mass torts lawyer effectively ran a Ponzi scheme illustrates how litigation funding arrangements can subject attorneys to legal ethics dilemmas and potential liability, so engagement letters must have very clear terms, says Matthew Feinberg at Goldberg Segalla.

  • E-Discovery Quarterly: Recent Rulings On Dynamic Databases

    Author Photo

    Several recent federal court decisions illustrate how parties continue to grapple with the discovery of data in dynamic databases, so counsel involved in these disputes must consider how structured data should be produced consistent with the requirements of the Federal Rules of Civil Procedure, say attorneys at Sidley.

  • How Litigating Antitrust Fix Helped GTCR Prevail In Court

    Author Photo

    An Illinois federal judge's recent denial of the Federal Trade Commission's injunction request in the GTCR acquisition of Surmodics joins a developing series of cases in which deal parties have prevailed against government antitrust challenges by proposing a post-complaint fix and litigating the as-amended deal, say attorneys at Paul Weiss.

  • Series

    Building With Lego Makes Me A Better Lawyer

    Author Photo

    Building with Lego has taught me to follow directions and adapt to unexpected challenges, and in pairing discipline with imagination, allows me to stay grounded while finding new ways to make complex deals come together, says Paul Levin at Venable.

  • The Rise Of Trade Secret Specificity As A Jury Question

    Author Photo

    Recent federal appellate court decisions have clarified that determining sufficient particularity under the Defend Trade Secrets Act is a question of fact and will likely become a standard jury question, highlighting the need for appropriate jury instructions that explicitly address the issue, says Amy Candido at Simpson Thacher.

  • Series

    Law School's Missed Lessons: Networking 101

    Author Photo

    Cultivating a network isn't part of the law school curriculum, but learning the soft skills needed to do so may be the key to establishing a solid professional reputation, nurturing client relationships and building business, says Sharon Crane at Practising Law Institute.

  • Defeating Estoppel-Based Claims In Legal Malpractice Actions

    Author Photo

    State supreme court cases from recent years have addressed whether positions taken by attorneys in an underlying lawsuit can be used against them in a subsequent legal malpractice action, providing a foundation to defeat ex-clients’ estoppel claims, says Christopher Blazejewski at Sherin and Lodgen.

  • Trade Secret Rulings Reveal The Cost Of Poor Preparation

    Author Photo

    Two recent federal appellate decisions show that companies must be prepared to prove their trade secrets with specificity, highlighting how an asset management program that identifies key confidential information before litigation arises can provide the clarity and documentation that courts increasingly require, say attorneys at Mintz.

  • Series

    The Biz Court Digest: How It Works In Massachusetts

    Author Photo

    Since its founding in 2000, the Massachusetts Business Litigation Session's expertise, procedural flexibility and litigant-friendly case management practices have contributed to the development of a robust body of commercial jurisprudence, say James Donnelly at Mirick O’Connell, Felicia Ellsworth at WilmerHale and Lisa Wood at Foley Hoag.

  • Why Appellees Should Write Their Answering Brief First

    Author Photo

    Though counterintuitive, appellees should consider writing their answering briefs before they’ve ever seen their opponent’s opening brief, as this practice confers numerous benefits related to argument structure, time pressures and workflow, says Joshua Sohn at the U.S. Department of Justice.

  • Navigating DEA Quotas: Key To Psychedelics Industry Growth

    Author Photo

    As new compounds like DOI enter the Schedule I landscape, manufacturers who anticipate U.S. Drug Enforcement Administration quota regulations, and build quota management into their broader strategy, will be best equipped to meet the growing demand, say Kimberly Chew at Husch Blackwell and Jaime Dwight at Promega.

  • Series

    Mindfulness Meditation Makes Me A Better Lawyer

    Author Photo

    Mindful meditation enables me to drop the ego, and in helping me to keep sight of what’s important, permits me to learn from the other side and become a reliable counselor, says Roy Wyman at Bass Berry.

  • Growth, Harmonization In Focus As Hague System Turns 100

    Author Photo

    One hundred years after its establishment, the Hague System has grown into an important pillar of international design protection, offering a promising path toward even greater harmonization in design law as its geographic reach continues to expand, say attorneys at Sterne Kessler.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.